Floatz logo

Dalteparin

Plasma Cell Myeloma

University of Southern Californiaother_biologicalPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

475 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
Vincristine Sulfate
Roswell Park Cancer Institute
Phase 3BBB
Cyclosporin A
Seoul National University Hospital
Phase 3BBB
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
University of Birmingham
Phase 4BBB

View all 50 →

Same molecule, other indications

Dalteparin is also rated in:

venous thromboembolismActive
BBB
Indicative · Phase 4
73 / 100
View asset →
precancerous conditionDormant
B
Indicative · Phase 3
62 / 100
View asset →
thrombotic diseaseActive
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →